<SEC-DOCUMENT>0001087294-26-000055.txt : 20260713
<SEC-HEADER>0001087294-26-000055.hdr.sgml : 20260713
<ACCEPTANCE-DATETIME>20260713172801
ACCESSION NUMBER:		0001087294-26-000055
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260713
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20260713
DATE AS OF CHANGE:		20260713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				621765329
		STATE OF INCORPORATION:			TN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		261172087

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST END AVENUE
		STREET 2:		SUITE 1300
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		1600 WEST END AVENUE
		STREET 2:		SUITE 1300
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20260713.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f4d00-e3b0-79be-8693-3c38ddfa5704,g:58ab6139-0ac0-4453-895e-309163ca93aa,d:c710ed9e8fad4247b8dbccb582486b77-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20260713</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20260713.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-07-13</xbrli:startDate><xbrli:endDate>2026-07-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic710ed9e8fad4247b8dbccb582486b77_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">July 13, 2026 (<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 13, 2026</ix:nonNumeric>)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1600 West End Avenue, Suite 1300</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic710ed9e8fad4247b8dbccb582486b77_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 &#160;&#160;&#160;&#160;Other Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On July 13, 2026, the Board of Directors of Cumberland Pharmaceuticals Inc., (the &#8220;Cumberland&#8221; or  &#8220;Company&#8221;) authorized and declared a special cash dividend of $1.50 per share of common stock payable in cash to the Company&#8217;s shareholders of record as of July 23, 2026. The dividend will be payable on or about July 31, 2026. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland previously announced the closing of a Strategic Transaction with Apotex Health Corp. (&#8220;Apotex&#8221;), an affiliate of Apotex, Inc., resulting in the integration of the U.S.-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the transaction with Apotex, an analysis by the Company&#8217;s tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland&#8217;s Board of Directors met to assess the Company&#8217;s future cash needs and evaluate possible alternatives for the excess capital. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares of common stock over time. This replaces the previous share repurchase program established in January 2019 that allowed $10 million of share repurchases, of which $2.1 million remained available. The timing and actual number of shares repurchased pursuant the Company&#8217;s repurchase program will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions, and other general business considerations. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On July 13, 2026, the Company issued a press release announcing the special cash dividend. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 in this Current Report on Form 8-K by reference.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the release is furnished as </span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="cumberlandannouncesspecial.htm">Exhibit 99.1.</a></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:22.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cumberlandannouncesspecial.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cumberlandannouncesspecial.htm">Press release dated July 13, 2026</a></span></div></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This filing contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s results of operations. These factors include market conditions, competition, the risks inherent in clinical development, regulatory review, and the commercialization of ifetroban and other pipeline or CET-supported assets, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company&#8217;s most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="ic710ed9e8fad4247b8dbccb582486b77_7"></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dated: July 13, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cumberlandannouncesspecial.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="iba5199588921444b8e8edcf8443ccefd_1"></div><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:84px;margin-bottom:5pt;vertical-align:text-bottom;width:372px"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:125%">CUMBERLAND PHARMACEUTICALS</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:125%">ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Record Date is July 23, 2026 &#38; Payment Date is July 31,2026</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">Corporate and Insider Share Purchase Initiatives to Continue</font></div><div style="margin-bottom:10pt;margin-top:9.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%">NASHVILLE, Tenn. (July 13, 2026) &#8211; Cumberland Pharmaceuticals Inc. (Nasdaq&#58; CPIX)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">, an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company&#8217;s common stock. The dividend will be payable on or about July 31, 2026, to the shareholders of record at the close of business on July 23, 2026. &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Cumberland previously announced the closing of a Strategic Transaction with Apotex Health Corp. (&#8220;Apotex&#8221;), resulting in the integration of the U.S.-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services. </font></div><div style="margin-bottom:10pt;margin-top:9.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Following the closing of the&#160;transaction with Apotex, an analysis by the Company&#8217;s tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland&#8217;s Board of Directors met to assess the Company&#8217;s future cash needs and evaluate possible alternatives for the excess capital.&#160;</font></div><div style="margin-bottom:10pt;margin-top:9.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares of common stock over time. The timing and actual number of shares repurchased pursuant the Company&#8217;s repurchase program will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions, and other general business considerations. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company.</font></div><div style="margin-bottom:10pt;margin-top:9.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">&#8220;In keeping with our ongoing commitment to deliver value to our shareholders, we are issuing a special dividend following the Strategic Transaction, which treats&#160;all shareholders equally,&#8221; said A.J. Kazimi, Cumberland&#8217;s CEO. &#8220;After the payout of $1.50 per share, we believe the Company will still have significant&#160;liquidity&#160;and&#160;financial flexibility to fund our long-term product development efforts,&#160;with&#160;additional reserves&#160;available&#160;to address any new opportunities&#8221;.</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%">Cumberland Emerging Technologies Inc</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">. Moving forward, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases&#58;</font></div><div style="padding-left:36pt;padding-right:14.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%;padding-left:28.2pt">Duchenne Muscular Dystrophy Cardiomyopathy&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations.</font></div><div style="padding-left:36pt;padding-right:14.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%;padding-left:28.2pt">Systemic Sclerosis&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone.</font></div><div style="padding-left:36pt;padding-right:14.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%;padding-left:28.2pt">Idiopathic Pulmonary Fibrosis&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S. Favorable interim safety findings have been announced, and the next milestone is the announcement of the efficacy results.</font></div><div style="padding-left:36pt;padding-right:14.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%;padding-left:28.2pt">Cancer Metastasis&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Cumberland, in collaboration with Vanderbilt Health, recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggest the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis.&#160;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">About Cumberland Pharmaceuticals</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:133%">Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. </font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">For more information, please visit&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">www.cumberlandpharma.com.</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s results of operations. These factors include market conditions, competition, the risks inherent in clinical development, regulatory review, and the commercialization of ifetroban and other pipeline or CET-supported assets, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company&#8217;s most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="padding-left:6.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.77pt;padding-right:4.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div style="padding-left:4.77pt;padding-right:4.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Shayla Simpson</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.77pt;padding-right:4.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div style="padding-left:4.77pt;padding-right:4.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Emily Kent</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</font></td><td colspan="3" style="padding:2px 1pt 2px 5.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Dalton Agency</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(615) 255-0068</font></td><td colspan="3" style="padding:2px 1pt 2px 5.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(540) 621-5448</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">###</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:0.5pt;font-weight:400;line-height:120%"><br></font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20260713.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f4d00-e3b0-79be-8693-3c38ddfa5704,g:58ab6139-0ac0-4453-895e-309163ca93aa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20260713" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20260713">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20260713_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20260713_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20260713_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f4d00-e3b0-79be-8693-3c38ddfa5704,g:58ab6139-0ac0-4453-895e-309163ca93aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019f4d00-e3b0-7f48-a706-2b06acdd0bac_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019f4d00-e3b0-7207-8cdd-e3d845e6b07a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019f4d00-e3b0-7c85-9243-4e4a6090dd7a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019f4d00-e3b0-7871-b7f9-98b30e52af0a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019f4d00-e3b0-79da-a9fe-152184c886ca_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019f4d00-e3b0-790b-aec5-abd5d4786b28_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019f4d00-e3b0-7b5d-9ef1-0922198814c0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019f4d00-e3b0-7bb3-816f-6ed2afe8d215_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019f4d00-e3b0-779c-8816-e0697c5bcd63_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019f4d00-e3b0-7c67-9ec0-0dea76d5875d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019f4d00-e3b0-7e94-8192-69a0af0cbd53_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019f4d00-e3b0-709d-bedc-9f5e6a3d28a0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019f4d00-e3b0-7463-b16b-bf4fac18ab47_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019f4d00-e3b0-7622-8b6c-70a4bcc69214_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019f4d00-e3b0-7b1b-a3ec-6221cb171862_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019f4d00-e3b0-7e3b-8a29-778e447ace4c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019f4d00-e3b0-7d70-86b5-d0ac05547052_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019f4d00-e3b0-7684-a894-99260bf5289b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019f4d00-e3b0-7ec8-9385-7eccab46cfc2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019f4d00-e3b0-7992-88e5-f3f75915e607_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019f4d00-e3b0-7479-9323-de3b74f86d4c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019f4d00-e3b0-7761-9ef1-6e69deafa32c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019f4d00-e3b0-7d11-9a83-13c22d8fb89c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20260713_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f4d00-e3b0-79be-8693-3c38ddfa5704,g:58ab6139-0ac0-4453-895e-309163ca93aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20260713.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019f4d00-e3b0-782e-a0d8-92fdda260a7f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_DocumentType_019f4d00-e3b0-782e-a0d8-92fdda260a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019f4d00-e3b0-7e10-87f5-fa04aad19780" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_DocumentPeriodEndDate_019f4d00-e3b0-7e10-87f5-fa04aad19780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019f4d00-e3b0-75d8-9635-97cfe2a326bc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityRegistrantName_019f4d00-e3b0-75d8-9635-97cfe2a326bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019f4d00-e3b0-7a56-b893-f45cb78819cb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityCentralIndexKey_019f4d00-e3b0-7a56-b893-f45cb78819cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019f4d00-e3b0-74df-9a97-514e20dd5bd5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_AmendmentFlag_019f4d00-e3b0-74df-9a97-514e20dd5bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019f4d00-e3b0-7919-89b1-ffb6890c2ac5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019f4d00-e3b0-7919-89b1-ffb6890c2ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019f4d00-e3b0-7527-9b35-e8413b5f0111" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityFileNumber_019f4d00-e3b0-7527-9b35-e8413b5f0111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019f4d00-e3b0-7236-81e3-b212106d9431" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityTaxIdentificationNumber_019f4d00-e3b0-7236-81e3-b212106d9431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019f4d00-e3b0-737a-817a-7e9a9db461f8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_CityAreaCode_019f4d00-e3b0-737a-817a-7e9a9db461f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019f4d00-e3b0-73b4-aabc-288b7f41bdae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_LocalPhoneNumber_019f4d00-e3b0-73b4-aabc-288b7f41bdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019f4d00-e3b0-7fce-bf8c-9edfcb302423" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_WrittenCommunications_019f4d00-e3b0-7fce-bf8c-9edfcb302423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019f4d00-e3b0-726e-aee2-3a959f67e036" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_SolicitingMaterial_019f4d00-e3b0-726e-aee2-3a959f67e036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019f4d00-e3b0-72ac-a407-f2ca727e6250" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_PreCommencementTenderOffer_019f4d00-e3b0-72ac-a407-f2ca727e6250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019f4d00-e3b0-7e8f-898b-675f0c5115d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019f4d00-e3b0-7e8f-898b-675f0c5115d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019f4d00-e3b0-7b38-bcac-139d159e5782" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_Security12bTitle_019f4d00-e3b0-7b38-bcac-139d159e5782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019f4d00-e3b0-7c5a-9c09-08ed7ba4bc6f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_TradingSymbol_019f4d00-e3b0-7c5a-9c09-08ed7ba4bc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019f4d00-e3b0-7488-abfd-845884f39e4a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_SecurityExchangeName_019f4d00-e3b0-7488-abfd-845884f39e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019f4d00-e3b0-7613-8fcb-5b3862c307ef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityEmergingGrowthCompany_019f4d00-e3b0-7613-8fcb-5b3862c307ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019f4d00-e3b0-7930-bb95-8dbec396374e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityAddressAddressLine1_019f4d00-e3b0-7930-bb95-8dbec396374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019f4d00-e3b0-719f-bd86-f6e65c6cf051" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityAddressCityOrTown_019f4d00-e3b0-719f-bd86-f6e65c6cf051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019f4d00-e3b0-7821-9c1e-6e8cdb353d61" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityAddressStateOrProvince_019f4d00-e3b0-7821-9c1e-6e8cdb353d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019f4d00-e3b0-7a9f-96aa-708f2db35d1e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f4d00-e3b0-7e92-9884-02e51d959c98" xlink:to="loc_dei_EntityAddressPostalZipCode_019f4d00-e3b0-7a9f-96aa-708f2db35d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 70# 2(  A$! Q$!_\0
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MC@O+6:0+O*13QR.%SC=M1B=N>-V,9XS4\DT,2-))(B(BL[NS *JH"68D\ *
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M:-J<-UI^IZ9J%I-+;7UC>P3V=W!+)'<02!L@7PK86'AD^%M M-.T32+;0/\
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MZ<\8)_(')^@YJ.2:,J5R 6RJ[CM!;;N(SD'(7!..F17\D_\ PY6_X+BCD?\
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M+:VTOA6Q-"@X1JU(P=1M03>LFK722UZW\[.U['])Q."!C).<?AZ__6S]*:7
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M SN5BC9@J@LQ& "2*_$7X,-^U5^S!^W'J/BKXU?"CPKX>^"W[=.KV.F:U8?
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MX3U1]#T'5M1M]#^)%WX)UVZ2S>W@TQ[QEMS]XM<*JJ<9+%@%##/RG&!QRV2
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M1PJJ2=J@  < 8HHHLNW]:_YO[V%EV_I;$M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Jul. 13, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 13,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue, Suite 1300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20260713.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20260713.htm">cpix-20260713.htm</File>
    <File>cpix-20260713.xsd</File>
    <File>cpix-20260713_lab.xml</File>
    <File>cpix-20260713_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20260713.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20260713",
   "dts": {
    "inline": {
     "local": [
      "cpix-20260713.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20260713.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20260713_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20260713_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20260713.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20260713.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001087294-26-000055-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001087294-26-000055-xbrl.zip
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M'S U!\:"6?X<$Q^TQVXYL+R#_NOM0&O:_H#M/;#M2IDRL1-XCQX#WG4H^N[
M6V)6^<#?#KQ9VUW!^^S(F_.)C-?/!,0-R;I*$*VX610 ZVUL5;NS'^>T];I=
M=:H['].6[(I3?I(#40\Z'-U?@+CM4.62[92./N=L-6.W28ROE"UF;[.ZI TU
MC7MTM+<^)7R%=>"FT,0?$C^D4FYQ'O==<$90G:GI34;].#R82^5])E^R0Y5O
ME&UG60V+QA/+[3[8Q;LAAR<SX[G SNTT<>:CK&?=L^!QQ(,@9,_/V!TB2K-7
M35ROK]5[ZM)4"TUTBD 8/17[-X<DBDE"!;FE8;JYC.%!N/\0RU9BR0R*L2=3
MF=1 )A?=OUZ*^\]CC/9?.+G.Y)ZJ*39</BI#>[9X2N;6P>2U>J>M?Y-W8=RG
M(?B!(7B"Y ,5-TS=*];UYZK[Y?=VHP ]?4;Z$^+K1#NXE3=@S)DN=%C*@G-)
M@#H($]#SO";7(KY30PP8$LR,4TD"-H I="6C23PZE=Q57LHZFBKI$CGX]6?W
MJ'JLDX]Y8ZYK(!.L@<1B"A-U>'W+6S/6NM+KZ: 8@<SZS0UK/T$X\B6#LLX&
M%K]0GGG7X^"<_'>:^K8A_N$[>\Y3A>1/M>Y]CUJ[@WOT$8\CURHW7SG=&H+J
M:K,&JAO%.MQ-)=.M0,[9&1I>W>4Z!#:W^%"<>JYP@I/KF]6(T0B6!6\$N^42
M^H%!H)&/F5OJ^UB*B8WQEFU 12#-Z5FP*=8N'=!IK#VOZ?;.%0J/A*3[("17
MHO[\GF'9KNK,6FRXUA LI%@[L'+S<+;AZYW>F76A?=B84[7:Y:'+BKM>FBQ/
M+TT.IU?_$GK-K+Y@],:B S":#1K>T8G$P'K]S<JR9U;\&3<K<1>V0(Z"^JHA
MTQ'@=7(\ET99NMKT=RH5'TR>M;3"*)YB(U*S'9?@3N,<K_[[7.^?';S5(3="
M9>-2MK_G\0PL6"V%\( %YQ%9N(YSJ)7TMQBT&C7VE M0XECH"IJVKH\(0>?)
MQ9""QODLU?ZC)-W(MP_) ?;]]>>:!Y9\UE@_<(_1FDQ?&L7-WKPF-%7#6 #9
M <'1 ^:'%#-WU%RK *OC4SDDP#N\ *TI^\6U*P[:,"*!%AW,^B9JDA@U0<0T
MT4DY\&%T7[!'2-W<S&[U6)K.PS@$-UJ:2QT^^-3H!,$/S1DOXXRMKXM-2;CC
M84CZ;#J/J1BE_3A5IE_)S?MMDUE\?I784*8QDW&"MM_46= H IOOX_X!//!#
ML&Q8:@'[%L2H O:F:S#>5[BU4&/R]3;22F)8$OF=T1!^M6.1V.C3:028=SD
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MWU#W@L/#)]S^[SUS9VAWQ[SW!U!+ P04    " !]J^U<[_L[@4X)  ",50
M%0   &-P:7@M,C R-C W,3-?;&%B+GAM;,6<;6^C.A;'W_=3>+-O=J7KAF=P
M->W5;._,JMK>F6K:T;W:JU5E;-.B(5 Y].G;KR%)"\$0VR3,FS8/SOF?_PF_
MG .!?/CU99&!)\:7:9&?SNQC:P983@J:YG>GL^\WGV$T^_7LZ.C#WR#\\U_?
M+L%O!7E<L+P$YYSADE'PG);WH+QGX(^"_TB?,+C*<)D4? 'A6?VR\^+AE:=W
M]R5P+"?8+-L\RT\L&R4>M2S(W-B"(8H9C +D0I>X$:4)]D/+^^7NQ(]P'-@N
M@A8F%O0\WX41\AET+60'+L'(Q:N@69K_.*G^Q'C)@+"7+^N[I[/[LGPXF<^?
MGY^/7V*>'1?\;NY8ECO?K)ZME[]TUC^[]6H;(32OGWU;NDQE"T58>_[G[Y?7
MY)XM,$SS98ES4@DLTY-E_>!E07!95WUG7J!W174/;I;!ZB%H.]"UCU^6='9V
M!,"J'+S(V#>6@.K_]V\7O9)H7JV8Y^RN>F^O&$\+>EUB7E[BF&4B^SI:^?K
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M(N0$5ISX3H1BO98I%YJF5ZZU&]U@HZ_;(7O*I=H:QQ?!J"<:^#?HA,/F1K3
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M,0)<N(6@792V5?RC$QXFY:T#^6%2ZIT!C1/N%F22(&-DPCA6H5#]4.@01"=
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MU+.NN['A<2MR&%%](J-IKGZP-^5]L9V"^X:D9@DR"22Q2I3!\1 ;%3N.N[T
MY7&7<@A!?6*BW8G]8*]L>9>YI=+NBWW$/2 10 DPI26-J4X&!&/+>S<Z/&Y=
M#B:M3XA<E54M\G^SQ;Y-&>% YXD0*,7,A$T:F@PXHVSX[H:'QQW-@60=#(Y7
MXQTEW0SW[>SH\43ST;QS?W;T'U!+ P04    " !]J^U<-[9?(DL/  ##1@
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M57 L<Y!-A/=.I(OEQV^?=6$O^Z?'_WM>R>8OXVA%G<Q1#6H4.LO,&.HR67V
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M]&5J0JKIK?*2X0653]8@SWM!80G90AN*S%7S8:QF<1'1-M8QTD= K/1F*C\
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M(!AW*1QJ?2Q5I,:Z@!5G?N6*X1!N$[JU7$^25WLC^@D=*41!:>E,:35*;A+
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M-S$S+FAT;5!+ 0(4 Q0    ( 'VK[5P02_WA?0(  &8'   1
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@<&5C:6%L+FAT;5!+!08     !0 % % !  #L-0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>cpix-20260713_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20260713.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2026-07-13</startDate>
            <endDate>2026-07-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-07-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1600 West End Avenue, Suite 1300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
